Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.
Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference
Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.
VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.
Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy
Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy
Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference
Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference
Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference
Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test
Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology
Biodesix raises an additional $7 million in series F financing.
Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.